Haemonetics Corp (HAE)
88.96
+0.62
(+0.70%)
USD |
NYSE |
May 28, 16:00
88.99
+0.03
(+0.03%)
Pre-Market: 20:00
Haemonetics Cash from Financing (TTM): 38.16M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 38.16M |
| December 31, 2023 | 100.06M |
| September 30, 2023 | -59.05M |
| June 30, 2023 | -77.57M |
| March 31, 2023 | -100.36M |
| December 31, 2022 | -107.53M |
| September 30, 2022 | -59.88M |
| June 30, 2022 | -37.51M |
| March 31, 2022 | -15.75M |
| December 31, 2021 | 425.78M |
| September 30, 2021 | 277.87M |
| June 30, 2021 | 216.87M |
| March 31, 2021 | 367.45M |
| December 31, 2020 | -53.94M |
| September 30, 2020 | 49.85M |
| June 30, 2020 | 1.653M |
| March 31, 2020 | -131.21M |
| December 31, 2019 | -135.58M |
| September 30, 2019 | -165.64M |
| June 30, 2019 | -53.20M |
| March 31, 2019 | -50.63M |
| December 31, 2018 | -170.28M |
| September 30, 2018 | -85.76M |
| June 30, 2018 | -98.43M |
| March 31, 2018 | -120.64M |
| Date | Value |
|---|---|
| December 31, 2017 | -18.44M |
| September 30, 2017 | -72.13M |
| June 30, 2017 | -58.98M |
| March 31, 2017 | -60.41M |
| December 31, 2016 | -65.62M |
| September 30, 2016 | -23.22M |
| June 30, 2016 | -37.84M |
| March 31, 2016 | -62.62M |
| December 31, 2015 | -44.45M |
| September 30, 2015 | -41.68M |
| June 30, 2015 | -34.12M |
| March 31, 2015 | -33.16M |
| December 31, 2014 | -41.71M |
| September 30, 2014 | -52.29M |
| June 30, 2014 | -59.01M |
| March 31, 2014 | -20.70M |
| December 31, 2013 | -43.85M |
| September 30, 2013 | -36.83M |
| June 30, 2013 | 455.13M |
| March 31, 2013 | 461.85M |
| December 31, 2012 | 496.28M |
| September 30, 2012 | 506.10M |
| June 30, 2012 | -18.71M |
| March 31, 2012 | -30.47M |
| December 31, 2011 | -31.63M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-165.64M
Minimum
Sep 2019
425.78M
Maximum
Dec 2021
24.02M
Average
-45.36M
Median
Cash from Financing (TTM) Benchmarks
| ResMed Inc | -914.60M |
| Stryker Corp | -1.531B |
| InfuSystems Holdings Inc | -7.084M |
| Perspective Therapeutics Inc | 167.19M |
| Xtant Medical Holdings Inc | 20.30M |